Genome-wide screenings of large amounts of primary breast tumors have led to the identification of the co-existing of mutations in multiple genes including KRAS, PIK3CA, MAP3K1, MAP2K4, PTEN and TP53 in primary breast tumors prior to treatment [10,11]. The gene discussed is KRAS; the disease is breast neoplasm.